Bupranolol

Bupranolol
Clinical data
AHFS/Drugs.com International Drug Names
Routes of
administration
Oral, topical (eye drops)
ATC code C07AA19 (WHO)
Pharmacokinetic data
Bioavailability < 10%
Protein binding 76%
Metabolism First pass elimination > 90%
Biological half-life 2-4 hours (plasma)
Excretion > 88% renal (as carboxybupranolol)
Identifiers
CAS Number 23284-25-5 N
PubChem (CID) 2475
IUPHAR/BPS 550
DrugBank DB08808 YesY
ChemSpider 2381 YesY
UNII 858YGI5PIT YesY
KEGG D07590 N
ChEMBL CHEMBL305380 YesY
Chemical and physical data
Formula C14H22ClNO2
Molar mass 271.78298 g/mol
3D model (Jmol) Interactive image
 NYesY (what is this?)  (verify)

Bupranolol is a non-selective beta blocker without intrinsic sympathomimetic activity (ISA), but with strong membrane stabilizing activity. Its potency is similar to propranolol.

Uses and dosage

Like other beta blockers, oral bupranolol can be used to treat hypertension and tachycardia. The initial dose is 50 mg two times a day. It can be increased to 100 mg four times a day. Bupranolol eye drops (0.05%-0.5%) are used against glaucoma.

Pharmacology

Bupranolol is quickly and completely absorbed from the gut. Over 90% undergo first-pass metabolism. Bupranolol has a plasma half life of about two to four hours, with levels never reaching 1 µg/l in therapeutic doses. The main metabolite is carboxybupranolol, 4-chloro-3-[3-(1,1-dimethylethylamino)-2-hydroxy-propyloxy]benzoic acid that is, the methyl group at the benzene ring is oxidized to a carboxyl group , of which 88% are eliminated renally within 24 hours.

Adverse effects, contraindications, interactions

Adverse effects, contraindications and interactions are similar to other beta blockers.

References

This article is issued from Wikipedia - version of the 6/11/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.